Northstrive Biosciences, a subsidiary of PMGC Holdings Inc. (ELAB), Thursday announced that it has received encouraging preliminary feedback from the U.S. Food and Drug Administration following its Type B pre-IND meeting request.
The FDA indicated that Northstrive's pharmacology and nonclinical studies support the safety and activity of its engineered probiotic candidate, EL-22, particularly in overweight and obese populations.
Given the FDA's supportive responses, Northstrive will forgo the pre-IND meeting and plans to submit an Investigational New Drug application in 2025 to begin a Phase 2 clinical trial evaluating EL-22 in combination with GLP-1 receptor agonists for obesity treatment. EL-22, designed to express myostatin on its surface, aims to preserve muscle mass a key challenge for patients on GLP-1 therapies.
The candidate has shown promising results in preclinical studies and was well-tolerated in a Phase 1 trial in South Korea. Production planning is underway with cGMP partners.
ELAB is currently trading at $2.54 down $0.37 or 12.68 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.